Working Money magazine.  The investors' magazine.
Traders.com Advantage

INDICATORS LIST


LIST OF TOPICS





Welcome to Traders.com Advantage!

TECHNICAL ANALYSIS  |  June 12, 2018
Staying Mindful
Regeneron Pharmaceuticals, Inc. (REGN) has been trading below its 50-day moving average since August 2017. Its stock, which once touched highs of 605, is now trading at 293. So what's in store for this stock? Is it wise to wait for an opportunity to short the stock, or is the worst behind it and should we look for a rebound?
by Stella Osoba, CMT

You must be a registered member of STOCKS & COMMODITIES magazine to read the article you’ve requested.

Already a subscriber
to STOCKS & COMMODITIES?
Click here to log in

Simply fill in your name and address and submit this form to us to receive your FREE TRIAL subscription to STOCKS & COMMODITIES.

This will begin your trial subscription at the special introductory rate of only $89.99 for 1 year. You will receive a trial issue of the magazine in the mail and also be able to access a sample digital issue of the magazine online in our subscriber area. In addition, you will have access to our online publications Working Money and Traders.com Advantage for 30 days!. Your log-in information will also be provided via the Email address you submit with the form below.

If you are not satisfied with your sample issue of Stocks & Commodities magazine, just return your bill marked “cancel” and owe nothing. The sample issue is yours to keep!

REQUEST YOUR FREE TRIAL TODAY












 

HELPQuestions or Comments? Send message to: Circ@Traders.com






S&C Subscription/Renewal




Request Information From Our Sponsors 

DEPARTMENTS: Advertising | Editorial | Circulation | Contact Us | BY PHONE: (206) 938-0570

PTSK — The Professional Traders' Starter Kit
Home — S&C Magazine | Working Money Magazine | Traders.com Advantage | Online Store | Traders’ Resource
Add a Product to Traders’ Resource | Message Boards | Subscribe/Renew | Free Trial Issue | Article Code | Search

Copyright © 1982–2024 Technical Analysis, Inc. All rights reserved. Read our disclaimer & privacy statement.